Last reviewed · How we verify
VX-809 & VX-770
At a glance
| Generic name | VX-809 & VX-770 |
|---|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®. (NA)
- Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators
- Personalized Theratyping Trial (EARLY_PHASE1)
- Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)
- Cystic Fibrosis Blood Neutrophils (NA)
- Mutation-specific Therapy for the Long QT Syndrome (PHASE2)
- Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation (PHASE3)
- Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VX-809 & VX-770 CI brief — competitive landscape report
- VX-809 & VX-770 updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI